Publications by authors named "Michelle Hoarty"

Claim this Profile
D
Discovery of Zilucoplan: A Complement C5 Inhibitor for Treatment of Anti-Acetylcholine Receptor (AChR) Antibody-Positive Generalized Myasthenia Gravis (gMG).
Ping Ye, Robert P Hammer, Zhaolin Wang, Ketki Dhamnaskar, Michelle Hoarty

J Med Chem· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation.
Guo-Qing Tang, Yalan Tang, Ketki Dhamnaskar, Michelle D Hoarty, Rohit Vyasamneni

Front Immunol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum: Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation.
Guo-Qing Tang, Yalan Tang, Ketki Dhamnaskar, Michelle D Hoarty, Rohit Vyasamneni

Front Immunol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myasthenia gravis complement activity is independent of autoantibody titer and disease severity.
Miriam L Fichtner, Michelle D Hoarty, Douangsone D Vadysirisack, Bailey Munro-Sheldon, Richard J Nowak

PLoS One· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial.
James F Howard, Richard J Nowak, Gil I Wolfe, Miriam L Freimer, Tuan H Vu, Michelle Hoarty

JAMA Neurol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis